Topic

Drugs

30
Jun
2016

Pfizer, GSK, AbbVie Join $51.5M Bet on Computational Drug Discovery Shop, Morphic Therapeutic

Integrins were a big deal in the early days of biotech in the 1980s and 1990s. They looked like a promising class of receptors found on cells implicated in many diseases. Billion-dollar dreams were in the air. Then, thunderstruck by dangerous and surprising side effects, integrin-directed drugs were tossed in the trash. But integrin biology is making a comeback with...
Read More
9
May
2016

Bull Market or Bubble? Watch My Chat with Biotech Leaders at Milken Global

Is biotech poised for growth? Or will it struggle to adapt in a world of healthcare cost containment? I’m optimistic about the fundamentals of the industry, and said so in my opening keynote talk at the Bloom Burton Healthcare Conference in Toronto, and again at the Milken Global Conference in Los Angeles. Instead of The Edge column this week, I wanted to...
Read More